文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

抗菌药物消耗趋势:COVID-19大流行的长期影响

Trends in antimicrobial consumption: long-term impact of the COVID-19 pandemic.
PubMed 文献 · Clin Microbiol Infect · 2024-12-09

该研究利用IQVIA MIDAS数据库中69个国家2016年11月至2023年12月的抗菌药物月度销售数据,分析COVID-19疫情后抗菌药物消耗的变化趋势。结果显示68个国家出现多个变化点,其中61个国家在疫情开始后抗菌药物消耗下降,但53个国家在2022年出现反向上升趋势;中断时间序列分析显示七国集团所有国家的行动限制措施对 antimicrobial consumption 有负面影响。

要点

  • 69个国家中68个在2016至2023年间出现一个以上变化点,其中61国在COVID-19疫情开始后抗菌药物消耗下降。
  • 上述61国中53国在2022年抗菌药物消耗出现反向上升趋势。
  • 中断时间序列分析显示,七国集团所有国家的行动限制措施对 antimicrobial consumption 有负面影响。

核心结论

  • 2020年全球抗菌药物消耗下降可能并非由COVID-19本身所致,而是由行动限制等非药物干预措施所致;人群流动性可能是人群层面抗菌药物使用的关键决定因素之一。

研究设计与样本

  • 利用IQVIA MIDAS信息服务获取69个国家抗菌药物月度销售数据,比较2020年相对2019年、2021年相对2020年、2022年相对2021年的抗菌药物消耗变化率,并对2016年11月至2023年12月全球月度抗菌药物销售时间序列数据检测变化点。
  • 抗菌药物定义为解剖治疗化学分类代码J1的口服和胃肠外药物,销售以IQVIA定义的标准单位报告,并以每1000人口每日标准单位评估,人口基于联合国《世界人口展望》数据。
  • 采用中断时间序列分析检验七国集团国家行动限制措施的影响。

主要发现

  • IQVIA MIDAS数据中,69个国家中有68个国家在2016年至2023年间出现一个以上变化点。
  • 上述68国中有61国在COVID-19疫情开始后抗菌药物消耗下降。
  • 上述61国中有53国在2022年抗菌药物消耗出现反向上升趋势。
  • 中断时间序列分析显示,行动限制措施对七国集团所有国家的抗菌药物消耗均有负面影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The COVID-19 pandemic was associated with a global decrease in antimicrobial consumption (AMC) in 2020. However, the persistence of this downwards trend is not known at a global level. This study examined the global and longer-term trends in AMC after the emergence of COVID-19. METHODS: The change rate of AMC was compared (a) 2020 over 2019, (b) 2021 over 2020, and (c) 2022 over 2021 using monthly sales volume data of antimicrobials in 69 countries obtained from the IQVIA MIDAS information service. Changepoints were detected using time-series data of global monthly antimicrobial sales from November 2016 to December 2023. We defined antimicrobials as oral and parenteral drugs classified as J1 by the Anatomical Therapeutic Chemical code. Antimicrobial sales were reported in standard units, as defined by IQVIA. We assessed the data using standard units per 1000 population per day, with populations based on World Population Prospects data issued by the United Nations. In addition, interrupted time-series analysis was used to examine the impact of movement restrictions in G7 countries. RESULTS: In the IQVIA MIDAS data, 68 of the 69 countries had more than one changepoint between 2016 and 2023. Of these 68 countries, 61 experienced a decrease in AMC after the COVID-19 pandemic started. However, 53 of these 61 countries showed a reverse increasing trend in AMC in 2022. Interrupted time-series analysis revealed that movement restrictions had a negative impact on AMC in all G7 countries. DISCUSSION: The global decrease in AMC in 2020 might not have been because of COVID-19 itself but to non-pharmaceutical interventions such as movement restrictions. Human mobility could possibly be one of the key determinants of antimicrobial use at the population level.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Tsuzuki S, Koizumi R, Asai Y, et al. Trends in antimicrobial consumption: long-term impact of the COVID-19 pandemic. Clin Microbiol Infect. 2024. PMID: 39653183. doi:10.1016/j.cmi.2024.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。